[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [GRAPHITE: "Essential for America's National Defense"]( [Discover Who's Poised to Benefit In The U.S. vs. China Energy War]( --------------------------------------------------------------- January 26, 2023 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers across all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- Sponsor Message [Apple, Amazon, and Walmart are Investing in Solar Energy]( global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market. [See How Investors Could Benefit]( --------------------------------------------------------------- [Nemaura Medical, NMRD]( Recent Analyst Action: Yi Chen, analyst at H.C. Wainwright, reiterates coverage on [Nemaura Medical (NMRD)](in the Healthcare sector with a Buy rating and a price target of $8.00 (1 day ago). - Recent Price: $$3.05 - Average Analyst Price Target: $10.50 (244.26%) - Market Cap: $$50.38M [TipRanks.com]( also reports that [Nemaura Medical](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.50 . The target pricing ranges from a high forecast of $13.00 down to a low forecast of $8.00. [Nemaura Medical (NMRD)](’s last closing price was $$3.05 which would put the average price target at $$10.50. Here are 3rd party ratings for [NMRD](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 37% (92 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Everyone knows America is nuts right now. But this is next-level crazy...]( Florida man pulls up to the service station… “Hacks” gas pump... And then THIS happens: [Click here to watch!]( --------------------------------------------------------------- [Xilio Therapeutics, XLO]( Recent Analyst Action: Michael Schmidt, analyst at Guggenheim, reiterates coverage on [Xilio Therapeutics (XLO)](in the Healthcare sector with a Buy rating and a price target of $9.00 (3 weeks ago). - Recent Price: $$4.48 - Average Analyst Price Target: $12.25 (173.44%) - Market Cap: $$76.92M [TipRanks.com]( also reports that [Xilio Therapeutics](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $12.25 . The target pricing ranges from a high forecast of $20.00 down to a low forecast of $7.00. [Xilio Therapeutics (XLO)](’s last closing price was $$4.48 which would put the average price target at $$12.25. Here are 3rd party ratings for [XLO](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 35% (88 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- [Pliant Therapeutics, PLRX]( Recent Analyst Action: David Lebovitz, analyst at Citigroup, reiterates coverage on [Pliant Therapeutics (PLRX)](in the Healthcare sector with a Buy rating and a price target of $55.00 (2 days ago). - Recent Price: $$35 - Average Analyst Price Target: $50.75 (45.00%) - Market Cap: $$1.48B [TipRanks.com]( also reports that [Pliant Therapeutics](currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $50.75 . The target pricing ranges from a high forecast of $60.00 down to a low forecast of $45.00. [Pliant Therapeutics (PLRX)](’s last closing price was $$35 which would put the average price target at $$50.75. Here are 3rd party ratings for [PLRX](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 35% (88 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Sell every Stock except ONE]( are down... But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month... [Ticker Revealed.]( --------------------------------------------------------------- [Sumo Logic, SUMO]( Recent Analyst Action: Brent Thill, analyst at Jefferies, reiterates coverage on [Sumo Logic (SUMO)](in the Technology sector with a Hold rating and a price target of $11.00 (2 days ago). - Recent Price: $$11.42 - Average Analyst Price Target: $12.75 (11.65%) - Market Cap: $$1.18B [TipRanks.com]( also reports that [Sumo Logic](currently has 6 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $12.75 . The target pricing ranges from a high forecast of $18.00 down to a low forecast of $10.00. [Sumo Logic (SUMO)](’s last closing price was $$11.42 which would put the average price target at $$12.75. Here are 3rd party ratings for [SUMO](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 26% (64 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- [Atara Biotherapeutics, ATRA]( Recent Analyst Action: Anthony Butler, analyst at EF Hutton, reiterates coverage on [Atara Biotherapeutics (ATRA)](in the Healthcare sector with a Buy rating and a price target of $25.00 (3 weeks ago). - Recent Price: $$4.835 - Average Analyst Price Target: $22.50 (365.36%) - Market Cap: $$394.70M [TipRanks.com]( also reports that [Atara Biotherapeutics](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $22.50 . The target pricing ranges from a high forecast of $31.00 down to a low forecast of $5.00. [Atara Biotherapeutics (ATRA)](’s last closing price was $$4.835 which would put the average price target at $$22.50. Here are 3rd party ratings for [ATRA](: - TipRanks.com: Strong Buy - TradingView.com: n/a (possibly response change) - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 35% (88 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [GRAPHITE: "Essential for America's National Defense"]( you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider. [Discover Who's Poised to Benefit In The U.S. vs. China Energy War]( --------------------------------------------------------------- [Shattuck Labs, STTK]( Recent Analyst Action: Joseph Pantginis, analyst at H.C. Wainwright, reiterates coverage on [Shattuck Labs (STTK)](in the Healthcare sector with a Buy rating and a price target of $28.00 (2 weeks ago). - Recent Price: $$3.7 - Average Analyst Price Target: $23.00 (521.62%) - Market Cap: $$126.32M [TipRanks.com]( also reports that [Shattuck Labs](currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $23.00 . The target pricing ranges from a high forecast of $28.00 down to a low forecast of $20.00. [Shattuck Labs (STTK)](’s last closing price was $$3.7 which would put the average price target at $$23.00. Here are 3rd party ratings for [STTK](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 35% (88 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- [2seventy bio, TSVT]( Recent Analyst Action: Matthew Harrison, analyst at Morgan Stanley, reiterates coverage on [2seventy bio (TSVT)](in the Healthcare sector with a Buy rating and a price target of $28.00 (2 days ago). - Recent Price: $$13.2 - Average Analyst Price Target: $29.33 (122.20%) - Market Cap: $$433.39M [TipRanks.com]( also reports that [2seventy bio](currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $29.33 . The target pricing ranges from a high forecast of $34.00 down to a low forecast of $28.00. [2seventy bio (TSVT)](’s last closing price was $$13.2 which would put the average price target at $$29.33. Here are 3rd party ratings for [TSVT](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Strong Buy, Top 35% (88 out of 250) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Apple, Amazon, and Walmart are Investing in Solar Energy]( global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market. [See How Investors Could Benefit]( --------------------------------------------------------------- And there you have it--7 Five Day Gainers across all US Exchanges. Sincerely, Editor, MarketTickerPress.com Market Ticker Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. By opening and/or clicking a link containted within this email, you are reconfirming your opt-in status. You can unsubscribe at any time. MarketTickerPress.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | North Carolina | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software